{"id":1809,"date":"2021-09-23T10:46:00","date_gmt":"2021-09-23T02:46:00","guid":{"rendered":"https:\/\/opentrons.com.cn\/news\/\/"},"modified":"2024-04-17T14:53:59","modified_gmt":"2024-04-17T06:53:59","slug":"opentrons-announces-200-million-series-c-round-led-by-softbank","status":"publish","type":"post","link":"https:\/\/opentrons.com.cn\/en\/news\/opentrons-announces-200-million-series-c-round-led-by-softbank\/","title":{"rendered":"Opentrons announces $200 million Series C financing led by SoftBank"},"content":{"rendered":"\n

Funding to expand Opentrons life sciences and healthcare automated laboratory platform<\/p>\n\n\n\n

September 23, 2021 08:00 EDT<\/p>\n\n\n\n

NEW YORK--(BUSINESS WIRE)--Today, Opentrons Labworks Inc. announced that SoftBank Vision Fund 2* has led a $200 million Series C investment in the company, with participation from Khosla Ventures. Opentrons will use the funding to further invest in its global automated laboratory platform.<\/p>\n\n\n\n

\"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been shackled by the slow, expensive, and overly complex laboratory solutions that underpinned their work\"<\/p>\n\n\n\n

\"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been hamstrung by the slow, expensive, and overly complex laboratory solutions that underpinned their work.\" Opentrons CEO Jon Brennan-Badal said. \"Opentrons' platform provides the key to unlocking its potential. We are driving more R&D, more testing, more biology to unlock innovation in life sciences and healthcare.\"<\/p>\n\n\n\n

This laboratory platform uniquely integrates the development of laboratory robotics, analysis and operations to create high-quality and cost-effective end solutions. Opentrons uses the platform to provide the following industry-specific laboratory solutions:<\/p>\n\n\n\n